

Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-Aug-2017
Document Type: USP Monographs
DocId: GUID-C22FB4A4-B358-49BF-996E-8198E9C8F208_1_en-US
DOI: https://doi.org/10.31003/USPNF_M63020_01_01
DOI Ref: 80pii

© 2025 USPC
Do not distribute

Phenazopyridine Hydrochloride Tablets

DEFINITION
Phenazopyridine Hydrochloride Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of phenazopyridine hydrochloride ($C_{11}H_{11}N_5 \cdot HCl$).

IDENTIFICATION

- A.** The UV spectrum of the phenazopyridine peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

- PROCEDURE**
Solution A: 20 mM ammonium acetate in water
Solution B: Acetonitrile
Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	95	5
2	95	5
15	50	50
20	50	50
28	30	70
33	30	70
35	95	5
40	95	5

Diluent: Acetonitrile and water (10:90)
Standard solution: 0.03 mg/mL of [USP Phenazopyridine Hydrochloride RS](#) in *Diluent*
Sample stock solution: Nominally 0.3 mg/mL of phenazopyridine hydrochloride from NLT 20 finely powdered Tablets in *Diluent*, prepared as follows. Transfer a suitable amount of the powder to a suitable volumetric flask. Add *Diluent* equivalent to 75% of the flask volume and sonicate for 15 min. Allow the solution to cool to room temperature, dilute with *Diluent* to volume, and centrifuge.
Sample solution: Nominally equivalent to 0.03 mg/mL of phenazopyridine hydrochloride in *Diluent* from the *Sample stock solution*
Chromatographic system
(See [Chromatography \(621\)](#), [System Suitability](#).)
Mode: LC
Detector: UV 280 nm. For *Identification A*, use a diode array detector in the range of 200–600 nm.
Column: 4.6-mm × 25-cm; 5-μm packing L1

Flow rate: 1 mL/min**Injection volume:** 20 µL**System suitability****Sample:** *Standard solution***Suitability requirements****Tailing factor:** NMT 2.0**Relative standard deviation:** NMT 1.0%**Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of the labeled amount of phenazopyridine hydrochloride ($C_{11}H_{11}N_5 \cdot HCl$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response from the *Sample solution* r_S = peak response from the *Standard solution* C_S = concentration of [USP Phenazopyridine Hydrochloride RS](#) in the *Standard solution* (mg/mL) C_U = nominal concentration of phenazopyridine hydrochloride in the *Sample solution* (mg/mL)**Acceptance criteria:** 90.0%–110.0%**PERFORMANCE TESTS**• [DISSOLUTION \(711\)](#)**Medium:** Water; 900 mL**Apparatus 2:** 50 rpm**Time:** 45 min**Standard solution:** [USP Phenazopyridine Hydrochloride RS](#) in *Medium***Sample solution:** Filter portions of the solution under test and suitably dilute with *Medium* to a concentration that is similar to that of the *Standard solution*.**Instrumental conditions****Mode:** UV**Analytical wavelength:** 422 nm**Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the quantity of phenazopyridine hydrochloride ($C_{11}H_{11}N_5 \cdot HCl$) dissolved by using UV absorption from the *Sample solution* in comparison with the *Standard solution*.**Tolerances:** NLT 75% (Q) of the labeled amount of phenazopyridine hydrochloride ($C_{11}H_{11}N_5 \cdot HCl$) is dissolved.• [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements**IMPURITIES**• **ORGANIC IMPURITIES****Solution A, Solution B, Mobile phase, and Diluent:** Proceed as directed in the Assay.**Sensitivity solution:** 0.25 µg/mL of [USP Phenazopyridine Hydrochloride RS](#) in *Diluent***Standard solution:** 0.001 mg/mL of [USP Phenazopyridine Hydrochloride RS](#) in *Diluent***Sample solution:** Nominally 0.5 mg/mL of phenazopyridine hydrochloride from NLT 20 finely powdered Tablets in *Diluent*, prepared as follows.Transfer a suitable amount of the powder to a suitable volumetric flask. Add *Diluent* equivalent to 60% of the flask volume and sonicate for 15 min. Allow the solution to cool to room temperature and dilute with *Diluent* to volume. Centrifuge the solution and dilute the supernatant with *Diluent* to obtain 0.5 mg/mL of phenazopyridine hydrochloride.**Chromatographic system:** Proceed as directed in the Assay except for the *Detector*.**Detector:** UV 240 nm**System suitability****Samples:** *Sensitivity solution* and *Standard solution***Suitability requirements****Tailing factor:** NMT 1.5 for the phenazopyridine peak, *Standard solution***Relative standard deviation:** NMT 3.0% for the phenazopyridine peak, *Standard solution*

Signal-to-noise ratio: NLT 30 for the phenazopyridine peak, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of any individual unspecified impurity in the portion of the Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of each individual unspecified impurity from the *Sample solution*

r_S = peak response of phenazopyridine from the *Standard solution*

C_S = concentration of [USP Phenazopyridine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of phenazopyridine hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 2](#). Disregard any impurity peaks less than 0.05%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
2,6-Diaminopyridine ^a	0.37	—
Phenazopyridine	1.00	—
Individual unspecified impurity	—	0.2
Total impurities	—	2.0

^a For identification only. These are process impurities monitored in the drug substance and are not included in the total impurities.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store at controlled room temperature.
- **USP REFERENCE STANDARDS (11).**
[USP Phenazopyridine Hydrochloride RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PHENAZOPYRIDINE HYDROCHLORIDE TABLETS	Documentary Standards Support	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(2)

Current DocID: GUID-C22FB4A4-B358-49BF-996E-8198E9C8F208_1_en-US

DOI: https://doi.org/10.31003/USPNF_M63020_01_01

DOI ref: [80pii](#)